Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年 创立，公司目前正布局多款癌症实验性疗法研发管线。 来源：智通财经网 生物医药公司Eikon Therapeutics(EIKN.US)周三表示，其美国首次公开发行(IPO)募资3.812亿美元，共发 行约2120万股普通股，发行价定为每股18美元。此次发行价位于该公司16至18美元目标区间上限。 据了解，本次上市计划进行之际，美国IPO市场在2026年已显现回暖迹象。去年10月的政府停摆曾导致 多家企业推迟上市计划。而今年初，生物科技企业IPO同样迎来复苏，SpyGlass Pharma(SGP.US)、 AgomAb Therapeutics(AGMB.US)等生物医药研发企业均已在1月递交美国上市申请。 公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期 临床试验，该研究的中期分析数据预计将于2026年下半年公布。 Eikon Therapeutics的股票将于周四在纳斯达克挂牌 ...

Eikon Therapeutics的股票将于周四在纳斯达克挂牌交易，股票代码为"EIKN"。本次IPO的承销商包括摩 根大通、摩根士丹利、美国银行证券、Cantor及瑞穗证券。 Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年 创立，公司目前正布局多款癌症实验性疗法研发管线。 公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期 临床试验，该研究的中期分析数据预计将于2026年下半年公布。 生物医药公司Eikon Therapeutics(EIKN.US)周三表示，其美国首次公开发行(IPO)募资3.812亿美元，共发 行约2120万股普通股，发行价定为每股18美元。此次发行价位于该公司16至18美元目标区间上限。 据了解，本次上市计划进行之际，美国IPO市场在2026年已显现回暖迹象。去年10月的政府停摆曾导致 多家企业推迟上市计划。而今年初，生物科技企业IPO同样迎来复苏，SpyGlass Pharma(SGP.US)、 Ago ...

Group 1 - Eikon Therapeutics raised $381.2 million in its U.S. initial public offering [1] - The company sold approximately 21.2 million shares at a price of $18 each [1]

Eikon Therapeutics, a late-stage cancer drug developer led by Merck veterans, raised $381.2 million in an upsized US initial public offering https://t.co/ETqqNtgxuj ...

Company Overview - Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address serious unmet medical needs, particularly in oncology [6] - The company aims to integrate traditional biology research with advanced engineering to expedite the development of better medicines [6] Initial Public Offering (IPO) Details - Eikon has priced its upsized initial public offering at $18.00 per share, offering a total of 21,177,600 shares, which is expected to generate approximately $381 million in gross proceeds [1] - The underwriters have a 30-day option to purchase an additional 3,176,640 shares at the same initial public offering price [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "EIKN" on February 5, 2026, with the offering expected to close on or about February 6, 2026 [2] Regulatory and Compliance Information - A registration statement on Form S-1 related to the offering has been filed with the SEC and was declared effective on January 30, 2026 [3] - The offering is being conducted solely through a prospectus that is part of the effective registration statement [4]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a star-studded biotechnology startup that raised more than $1 billion in venture funding, said Wednesday it has secured $381 million more through an initial public offering. The California biotech sold over 21 million shares at $18 apiece, far more than it initially set out to sell when it set terms for its offering last week. Shares will ...

Group 1: Recent IPOs - Last week, 15 new stocks were listed, including one direct listing company, Public Policy Holding (PPHC), which raised $50.84 million by issuing 4.15 million shares at $12.25 per share [1] - York Space System (YSS) raised $629 million by issuing 18.5 million shares at $34 per share [1] - Picpay (PICS) raised $434 million by issuing 22.86 million shares at $19 per share [1] - Ethos Technologies (LIFE) raised $200 million by issuing 10.53 million shares at $19 per share [1] Group 2: Upcoming IPOs - Jaguar Uranium Corp. plans to list on NYSE MKT with the ticker JAGU on February 3, 2026, aiming to raise up to $30 million by issuing 6 million shares at $4 to $6 per share [3][5] - VeraDermics, Inc. plans to list on NYSE with the ticker MANE on February 4, 2026, aiming to raise up to $214 million by issuing 13.35 million shares at $14 to $16 per share [8] - Eikon Therapeutics, Inc. plans to list on NASDAQ with the ticker EIKN on February 5, 2026, aiming to raise up to $318 million by issuing 17.65 million shares at $16 to $18 per share [10] - Bob's Discount Furniture, Inc. plans to list on February 5, 2026, aiming to raise up to $370 million by issuing 19.45 million shares at $17 to $19 per share, with projected revenue of $1.719 billion and a net profit of $80.7 million for the first nine months of 2025 [14] - Forgent Power Solutions, Inc. plans to list on NYSE with the ticker FPS on February 5, 2026, aiming to raise up to $1.624 billion by issuing 56 million shares at $25 to $29 per share, with revenue of $283 million and a net profit of $15.56 million for the last three months ending September 30, 2025 [18] - Once Upon a Farm, PBC plans to list on February 6, 2026, aiming to raise up to $209 million by issuing 11 million shares at $17 to $19 per share, with revenue of $177 million and a net loss of $39.76 million for the first nine months of 2025 [22] - Liftoff Mobile, Inc. plans to list on NASDAQ with the ticker LFTO on February 6, 2026, aiming to raise up to $762 million by issuing 25.4 million shares at $26 to $30 per share, with revenue of $492 million and a net loss of $25.65 million for the first nine months of 2025 [25] - Agomab Therapeutics NV plans to raise up to $213 million by issuing 12.5 million shares at $15 to $17 per share, with no revenue and a loss of $45.15 million for the first nine months of 2025 [28]

Core Insights - The AI boom is significantly driven by large-scale data centers that support the training and operation of advanced AI models like Gemini, ChatGPT, and Claude, impacting energy grids and the economy [1] Industry Developments - A $51 million data center project is being developed at Hassayampa Ranch in Arizona, with interest from major hyperscalers like Google, Microsoft, and OpenAI [2] - AI infrastructure investment is becoming a crucial part of U.S. economic growth, with bipartisan political efforts to expedite project approvals, reflecting the influence of tech investors [3] Political and Environmental Context - AI data centers have become a contentious political issue, with debates surrounding their impact on electricity costs, water supplies, and job creation, drawing criticism from both left-leaning and populist Republican figures [4] - The intersection of Big Tech, political interests, and local community needs is creating tensions as the demand for computing power increases [5]

Core Viewpoint - Eikon Therapeutics is aiming for a valuation of up to $908.2 million in its upcoming U.S. initial public offering, indicating a resurgence in biotech listings [1] Company Summary - Eikon Therapeutics is a drug developer that is preparing for an initial public offering (IPO) in the U.S. market [1] - The targeted valuation of $908.2 million reflects the company's growth potential and investor interest in the biotech sector [1] Industry Summary - The biotech industry is experiencing a comeback in public listings, suggesting renewed investor confidence and market activity [1]

Table of Contents As filed with the Securities and Exchange Commission on January 28, 2026. Registration No. 333-292633 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 EIKON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 2836 84-2807586 (Primary Standard Industrial Classification Code Number) 230 Harriet ...